ANIP Earnings

ANIP reported its FY2025Q3 earnings on 2025-11-07, showcasing a revenue of 228.00M against an estimate of 213.00M, resulting in a 7.03% surprise. The EPS was 2.04, surpassing the expected 1.36 by 50% . The stock experienced a 0.22% price change on the earnings day and a -3.28% change over the next five days, reflecting market reactions to the results.

Following ANIP's FY2025Q3 earnings announcement on 2025-11-07, the stock price moved by 0.22% on the day of the release. Over the subsequent five days, it saw a -3.28% change. Historically, ANIP's stock price tends to shift by an average of -4.58% in the 10 days leading up to earnings and -1.93% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ANIP’s annual revenue to reach 233.00M, while the EPS is projected at 2.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 2.07% and EPS estimates Revise Upward by 2.22% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ANIP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 2.07%, while EPS estimates moved Revise Upward by 2.22% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ANIP's stock price typically moves by -4.58% in the 10 days before its earnings and -1.93% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 2.00 and revenue of 233.00M.

The company has raised its revenue guidance significantly, indicating strong future growth expectations, particularly in the Rare Disease and Cortrophin Gel segments. Despite a slight decrease in gross margin, cash flow remains robust. The Q&A reveals optimism in multi-year growth opportunities and strategic focus on expanding the Rare Disease business. The market is promotion-sensitive, and the prefilled syringe is driving adoption. While there are competitive pressures, the company's strategic initiatives and optimistic guidance suggest a positive outlook, likely resulting in a 2% to 8% stock price increase over the next two weeks.